Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $8.45, for a total transaction of $96,727.15. Following the sale, the director now directly owns 7,188,563 shares of the company’s stock, […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00. Following the completion of the sale, the chief executive officer now owns […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $8.42, for a total value of $421,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 […]
Lingotto Investment Management LLP lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 141.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,875,077 shares of the company’s stock after buying an additional 1,100,000 shares during the period. Recursion […]
Elevatus Welath Management acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 24,650 shares of the company’s stock, valued at approximately $243,000. Other institutional investors also recently bought and sold shares of the […]